Antitussive offers convenient twice-daily dosing

July 26, 2004

The FDA recently approved codeine/chlorpheniramine (Codeprex, Celltech Group) extended-release suspension (CIII) for the temporary relief of cough, as may occur with the common cold or inhaled irritants, and for the temporary relief of runny nose; sneezing; itching of the nose or throat; and itchy, watery eyes due to hay fever, other upper respiratory allergies, or allergic rhinitis. The product is expected to be available in retail pharmacies by the fourth quarter.